U.S. NeuroSurgical Holdings, Inc. Stock

Equities

USNU

US90336K1016

Healthcare Facilities & Services

Market Closed - OTC Markets 11:26:19 2024-04-29 am EDT 5-day change 1st Jan Change
0.72 USD +1.41% Intraday chart for U.S. NeuroSurgical Holdings, Inc. -4.00% +60.00%
Sales 2022 - Sales 2023 - Capitalization 4.18M
Net income 2022 -1M Net income 2023 - EV / Sales 2022 -
Net cash position 2022 1.51M Net cash position 2023 381K EV / Sales 2023 -
P/E ratio 2022
-0.65 x
P/E ratio 2023
-5.12 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 71.75%
More Fundamentals * Assessed data
Dynamic Chart
U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
U.S. NeuroSurgical Holdings, Inc. announced that it expects to receive $2 million in funding CI
U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
U.S. NeuroSurgical Holdings, Inc. Appoints William St. Lawrence as a Non-Executive Director CI
U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
U.S. Neurosurgical Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
U.S. Neurosurgical Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
U.S. Neurosurgical Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
More news
1 day+1.41%
1 week-4.00%
Current month-10.00%
1 month-10.00%
3 months+41.51%
6 months+182.35%
Current year+60.00%
More quotes
1 week
0.71
Extreme 0.71
0.72
1 month
0.71
Extreme 0.71
0.80
Current year
0.42
Extreme 0.42
1.00
1 year
0.08
Extreme 0.08
1.00
3 years
0.04
Extreme 0.0432
1.00
5 years
0.04
Extreme 0.0432
1.00
10 years
0.04
Extreme 0.0432
1.00
More quotes
Managers TitleAgeSince
Chairman 79 93-06-30
Corporate Officer/Principal - -
Sales & Marketing 78 99-04-30
Members of the board TitleAgeSince
Director/Board Member 72 99-04-30
Director/Board Member 89 99-04-30
Director/Board Member 54 23-04-16
More insiders
Date Price Change Volume
24-04-29 0.72 +1.41% 1,100
24-04-26 0.71 -0.56% 500

Delayed Quote OTC Markets, April 29, 2024 at 11:26 am EDT

More quotes
U.S. NeuroSurgical Holdings, Inc., through its wholly-owned subsidiaries, holds interests in radiological treatment facilities. The Company owns and operates stereotactic radiosurgery centers, utilizing gamma knife technology. It owns, or holds interests in, the gamma knife and radiation treatment centers, and charges the hospital or medical facility, where the unit is housed and maintained, based on utilization. It is also focused on developing cancer centers featuring radiation therapy. These centers utilize linear accelerators with Intensity Modulated Radiation Therapy and Image Guided Radiation Therapy capabilities. It is focused on launching and development of Medicare advantage plans for seniors by its subsidiaries, Elite Health Plan and Elite Health Plan of Nevada, Inc. Medicare is the federal health insurance program for people ages 65 and over, to cover people under 65 with certain disabilities and people with end-stage renal disease requiring dialysis or kidney transplant.
More about the company